In recent years, a great deal of interest has developed in the use of bacterial agents as therapeutic tools in the treatment of malignant disease. Much effort has been directed toward the study of Bacillus Calmette-Gu6rin (BCG) and Corynebacterium parvum as immunotherapeutic agents. Both organisms have produced some promising results in clinical trials, most notably in the treatment of malignant melanoma. Neither organism is effective in the treatment of all tumor types, and in some cases adverse side effects occur.
Listeria monocytogenes, another intracellular parasite, has only recently been examined for possible antitumor properties. Youdim and coworkers (14) (15) (16) (17) (18) 
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It has been reported previously in this laboratory (4) that Listeria has potent antitumor effects in Strain 13 guinea pigs bearing a syngeneic methyicholanthrene (MCA)-induced fibrosarcoma. These inhibitory effects were expressed when Listeria was admixed with tumor cells before transplantation or when it was injected into established tumor nodules. Animals previously rejecting tumor-Listeria mixtures displayed enhanced skin test reactivity to a tumor extract as compared to animals rejecting untreated tumors. No significant mortality as a result of Listeria infection was ever observed.
The purpose of this study was to investigate the possible mechanisms of Listeria-mediated tumor inhibition using Strain 13 Organisms. The strain of L. monocytogenes used in these studies was originally obtained from D. W. Smith, Department of Medical Microbiology, University ofWisconsin-Madison. The growth characteristics and maintenance of this organism have been described previously (6) .
Tumor. The two fibrosarcomas used in this study, designated MCA-1 and MCA-2, were originally induced in this laboratory by injecting Strain 13 guinea pigs subcutaneously with 20 mg of 3-methylcholanthrene in 0.25 ml of corn oil. The induction and maintenance of these tumors has been described previously (4) . The MCA-1 tumor used in this study was in transplant generation 21 ALS. Heterologous antisera were prepared as previously described by Schell et al. (11) . Each of eight rabbits was injected intravenously with 2 ml of saline suspension containing 109 thymocytes obtained from newborn Strain 13 guinea pigs. Injection was via the marginal ear vein. Two weeks later each rabbit was reinjected intravenously with 2 ml of a saline suspension containing 109 thymocytes. One week after the last injection, rabbits were exsanguinated. Antisera were prepared and stored at -20'C until fractionated.
The antilymphocyte serum (ALS) and normal rabbit serum (NRS) were fractionated by precipitation with ammonium sulfate. After exhaustive dialysis against saline, the fractions were sterilized by filtration, and total protein content was determined as previously described (11) .
Titration of ALS. After absorption of ALS with guinea pig erythrocytes, leukoagglutinin levels were determined as previously described (11) . Serial twofold dilutions of the fractions were prepared using M-199 containing 10% NRS. A 0.1-ml sample of cell suspension containing 2 viable Listeria.
Histology. Tissues were fixed in buffered Formalin and sectioned at 5 tim. They were stained with hematoxylin and eosin and observed by light microscopy.
Statistical analysis. To evaluate the data concerning tumor size and mean survival time, comparisons between the control and Listeria-treated groups were carried out using Student's t test as described by Snedecor et al. (13) . To test the statistical significance of proportions in two independent samples, the chisquare (x2) test was used.
RESULTS
Growth pattern of MCA-1 tumor and effect of L. monocytogenes on tumor growth. When Strain 13 guinea pigs were injected subcutaneously with 2.5 x 106 MCA-1 tumor cells, the resulting tumors grew progressively in five of seven animals ( Table 1 ). In animals injected with a mixture of 2.5 x 106 MCA-1 cells and 2.5 x 104 viable Listeria, the tumors grew progressively for the first 7 days and then regressed completely. All seven animals were tumor free 14 days after injection of the Listeria-tumor cell mixture, demonstrating significant tumor inhibition (P < 0.01). The mean tumor diameter in Listeria-treated animals was slightly larger than in the group receiving tumor alone at days 3 and 7 posttransplantation, and this is probably due to the Listeria-induced influx of inflammatory cells. All animals in which tumor regression occurred remained free of tumor for 1 year, after which time they were used for the specificity experiment discussed below. The mean survival time of animals bearing progressively growing tumors without Listeria treatment was 58.6 days. At no time did animals receiving Listeriatumor mixtures exhibit overt symptoms of disease due to Listeria infection. Upon gross examination, the injection site of tumor-Listeria mixtures was erythematous and indurated for 3 to 4 days after injection. This confirms a previous study in this laboratory (4) showing marked tumor inhibition at Listeria-tumor cell rates of 1:100. Presence of specific antitumor immunity in guinea pigs receiving Listeria-tumor cell mixtures. To determine whether specific tumor immunity had developed, normal guinea pigs and guinea pigs previously rejecting Listeriatumor cell mixtures 12 to 14 months earlier were challenged with 2.0 x 106 MCA-1 or MCA-2 cells. Figure 2 shows the intense inflammatory reaction occurring 24 h after the intralesional injection of Listeria into an established tumor nodule. The upper part of the photograph is the dense tumor mass; the lower portion reveals the intense inflammatory reaction, consisting primarily of polymorphonuclear cells and a few lymphocytes. Figure 3 shows a higher magnification of the area shown in Fig. 2. Figure 4 shows the inflammatory reaction present 72 h after the injection of viable Listeria into an established tumor. Polymorphonuclear cells were still the predominant cell type in the inflammatory reaction site; in addition, many macrophages containing intracellular particles (arrow) and a few lymphocytes were seen. Untreated tumors revealed little or no inflammatory reaction. Salinetreated tumors revealed only a mild inflammatory reaction, consisting primarily of polymorphonuclear cells. Histological examination of animals previously rejecting Listeria-tumor inocula revealed no residual tumor cells at the injection site.
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DISCUSSION
The results of this study have shown that Listeria has a marked ability to inhibit an MCAinduced fibrosarcoma in Strain 13 guinea pigs. When normal guinea pigs were injected with an admixture of viable Listeria and MCA-1 cells in a ratio of one bacterium to 100 tumor cells, all animals showed complete rejection of the tumor. Animals remained tumor-free for at least 1 year. In animals receiving tumor cells alone, 71% of the animals developed progressively growing tumors leading to death by day 78. At no time did animals receiving Listeria-tumor mixtures exhibit gross symptoms of disease as a result of Listeria infection. This confirms a previous study in our laboratory by Dustoor et al. (4) in which complete inhibition of tumor cell inocula by Listeria was observed. Bast et al. (2) showed complete inhibition of the line 10 hepatoma when admixed with viable Listeria and injected into Strain 2 guinea pigs. In this system, however, a high number of Listeria (108) was necessary to achieve inhibition of growth; this dose proved fatal to a large number of animals and Results of the present study confirm the in vitro studies of Youdim and Sharman (18) , showing that macrophages and T lymphocytes are both required for tumor target cell killing in the presence of Listeria, and the in vivo study by Bast et al. (1) , showing that the effects of administration of heat-killed Listeria are sensitive to ALS treatment.
Experiments in which Listeria and tumor cells were injected in admixture into the flank of each guinea pig or injected separately on opposite flanks show that the Listeria and tumor cells must be in close proximity to each other for tumor inhibition to occur, confirming the report of Youdim (14) .
Listeria-mediated tumor inhibition thus seems to be similar to BCG-mediated regression in many ways. Both require viable organisms for optimal inhibition, close contact between the organism and the tumor cells is necessary, and the organisms are effective both when administered in admixture with the tumor inoculum and when injected into established tumor nodules of limited size; neither organism requires prior immunity, and both require an immunologically intact host for optimal results.
As with BCG inhibition, the mechanisms involved are not clearly understood. The most likely possibilities are that Listeria is directly toxic to tumor cells, or that tumor cells are destroyed as innocent bystanders by macrophages activated either directly by Listeria or via sensitized lymphocytes responding to Listeria antigens. Listeria could also have adjuvant properties permitting it to increase tumor-specific responses, thus leading to tumor destruction either directly by lymphocytes or by activated macrophages. The first possibilitynamely, that Listeria is directly toxic to tumor cells-seems unlikely because admixing Listeria and tumor cells in vitro does not cause a drop in viability, as determined by trypan blue exclusion.
The possibility exists that Listeria could mediate its effects by directly activating macrophages. Listeria and listerial cell wall antigens have been shown to act as murine B-cell mitogens (12) and to have adjuvant properties in increasing the antibody responses to both soluble and particulate antigens (3) . The in vitro studies of Youdim and co-workers (15, 16, 18) and the current study indicate that macrophages are not directly activated by Listeria because lymphocytes are required for killing to occur both in vitro and in vivo. Neither study, however, determines which cell is the actual killer cell. Krahenbuhl and Remington (8) have demonstrated that purified macrophages from Lis-VOL. 25, 1979 on November 3, 2017 by guest http://iai.asm.org/ Downloaded from teria-infected mice can be induced to kill tumor target cells in vitro in the presence of Listeria antigens. In contrast, Youdim found that both adherent and nonadherent cells were required in in vitro cultures for killing to occur. No role for antibody-mediated tumor inhibition has been identifed. It is known from previous studies in our laboratory that little or no antibody to Listeria antigens appears after primary infection of guinea pigs (5) . Antibodies to tumor antigens, however, might play a role in tumor growth inhibition and should be an area of future study. Due to the relative specificity of our ALS for T cell functions, however, we believe that it is most likely that T lymphocytes are required for in vivo tumor growth inhibition and that in vitro tumor cell killing is sensitive to anti-@ serum treatment, as demonstrated by Youdim (16) .
It is also plausible to speculate that the mechanism whereby enhanced tumor rejection occurs as late as 12 to 14 months after primary implantation of tumor cells admixed with Listeria involved T-cell function. Because of the persistence of apparent tumor immunity observed upon challenge with tumor cells in the absence of Listeria, it is possible that primary implantation with Listeria results in the persistence of Listeria-enhanced specific tumor immunity expressed in the form of specific T-cell function.
